Covalon Technologies

Covalon Technologies Current Assets

The Current Assets of Covalon Technologies (COV.V) as of Oct 18, 2026 is 7.40 M CAD. In the previous year, Current Assets was 25.13 M CAD — a change of -70.55% (lower).

Current Assets

7.40 MCAD

YoY

-70.55%

Last updated:

Current Assets of Covalon Technologies is 2025 7.40 M CAD. Current Assets of Covalon Technologies was 2024 25.13 M CAD. It decreases by -70.55% lower compared to the previous year.

The Covalon Technologies Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
17.14 M CAD
Jan 1, 2019
22.28 M CAD
Jan 1, 2020
14.85 M CAD
Jan 1, 2021
34.89 M CAD
Jan 1, 2022
25.86 M CAD
Jan 1, 2023
15.13 M CAD
Jan 1, 2024
25.13 M CAD
Jan 1, 2025
7.40 M CAD
The Covalon Technologies Current Assets history
YEARCurrent AssetsYoY
7.40 MCAD-70.55%
25.13 MCAD+66.10%
15.13 MCAD-41.49%
25.86 MCAD-25.89%
34.89 MCAD+134.96%
14.85 MCAD-33.34%
22.28 MCAD+29.97%
17.14 MCAD+75.26%
9.78 MCAD+128.45%
4.28 MCAD-19.06%
5.29 MCAD-1.93%
5.39 MCAD+79.54%
3.00 MCAD-6.48%
3.21 MCAD-47.95%
6.17 MCAD-12.16%
7.02 MCAD-8.91%
7.71 MCAD-41.58%
13.20 MCAD-22.23%
16.97 MCAD+200.79%
5.64 MCAD+291.59%
1.44 MCAD+41.28%
1.02 MCAD+24.39%
820,000.00CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Covalon Technologies Stock analysis

What does Covalon Technologies do? Covalon Technologies Ltd, listed on the TSX Venture Exchange under the ticker COV.V, is a biotechnology company based in Mississauga, Ontario, Canada. Founded in 2004, the company went public on September 3, 2004, with its initial public offering. Covalon specializes in the research, development, manufacturing, and marketing of patent-protected medical products. The company focuses on advanced wound care, infection prevention, and medical device coatings, offering solutions designed to reduce infections, minimize pain, and improve patient outcomes. Its products include specialized medical devices, medical dressings, and advanced technologies for perioperative care, antimicrobial skin protection, and complex wound closure. Covalon operates through two primary business models: developing and selling its own branded products and collaborating with other medical companies through development and licensing agreements. The company emphasizes compassionate care, creating products that are both patient-friendly and tailored for healthcare providers. Headquartered in Mississauga, Covalon leverages its patented technology platforms to address critical needs in medical care, particularly in reducing post-surgical infections and enhancing recovery processes. The company's solutions are intended to support both patients and medical professionals by providing effective, innovative approaches to wound management and infection control. Covalon's portfolio reflects a commitment to advancing medical technology with a focus on practical, patient-centered applications. Covalon Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Covalon Technologies stock

Current Assets of Covalon Technologies is 7.40 M CAD in 2025.

Current Assets of Covalon Technologies changed from 25.13 M CAD to 7.40 M CAD, representing a -70.55% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Covalon Technologies since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Covalon Technologies historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Covalon Technologies

All Key Metrics — Covalon Technologies